BE2014C016I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C016I2
BE2014C016I2 BE2014C016C BE2014C016C BE2014C016I2 BE 2014C016 I2 BE2014C016 I2 BE 2014C016I2 BE 2014C016 C BE2014C016 C BE 2014C016C BE 2014C016 C BE2014C016 C BE 2014C016C BE 2014C016 I2 BE2014C016 I2 BE 2014C016I2
Authority
BE
Belgium
Application number
BE2014C016C
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C016(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BE2014C016I2 publication Critical patent/BE2014C016I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
BE2014C016C 2002-11-15 2014-02-27 BE2014C016I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Publications (1)

Publication Number Publication Date
BE2014C016I2 true BE2014C016I2 (fr) 2023-03-07

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C016C BE2014C016I2 (fr) 2002-11-15 2014-02-27

Country Status (38)

Country Link
EP (2) EP1562603B3 (fr)
JP (1) JP4317138B2 (fr)
KR (1) KR101092247B1 (fr)
CN (3) CN101817800A (fr)
AR (2) AR041969A1 (fr)
AT (1) ATE430569T1 (fr)
AU (1) AU2003285326B2 (fr)
BE (1) BE2014C016I2 (fr)
BR (1) BRPI0316264B8 (fr)
CA (1) CA2506082C (fr)
CO (1) CO5570670A2 (fr)
CY (2) CY1110500T1 (fr)
DE (2) DE10253282A1 (fr)
DK (1) DK1562603T3 (fr)
EA (1) EA008665B1 (fr)
EC (1) ECSP055774A (fr)
ES (1) ES2326878T7 (fr)
FR (1) FR14C0049I2 (fr)
HR (1) HRP20050432B1 (fr)
HU (1) HUS1400011I1 (fr)
IL (1) IL167900A (fr)
LT (1) LTC1562603I2 (fr)
LU (1) LU92433I2 (fr)
ME (1) ME00354B (fr)
MX (1) MXPA05005081A (fr)
MY (1) MY136034A (fr)
NL (1) NL300650I2 (fr)
NO (2) NO334314B1 (fr)
NZ (1) NZ540661A (fr)
PE (1) PE20040694A1 (fr)
PL (1) PL212238B1 (fr)
PT (1) PT1562603E (fr)
RS (1) RS51607B (fr)
SI (1) SI1562603T1 (fr)
TW (1) TWI343812B (fr)
UA (1) UA81276C2 (fr)
WO (1) WO2004045618A2 (fr)
ZA (1) ZA200502246B (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
EP2422786B1 (fr) 2004-04-22 2014-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Nouvelles combinaisons de médicaments pour le traitement de maladies des voies aériennes
EP1789394A1 (fr) * 2004-05-13 2007-05-30 Boehringer Ingelheim International Gmbh Heterocycles benzocondenses substitues par hydroxy utilises comme beta-agonistes pour le traitement de maladies respiratoires
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
PL1917253T3 (pl) * 2005-08-15 2015-06-30 Boehringer Ingelheim Int Sposób wytwarzania betamimetyków
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
US20070088030A1 (en) * 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
EP2532679B1 (fr) 2005-10-21 2017-04-12 Novartis AG Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques
WO2007054498A1 (fr) * 2005-11-09 2007-05-18 Boehringer Ingelheim International Gmbh Formule aérosol pour inhalation
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1986644A1 (fr) * 2006-02-16 2008-11-05 Boehringer Ingelheim International GmbH Combinaisons medicamenteuses pour le traitement de pathologies des voies respiratoires
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
WO2008017638A1 (fr) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Nouveaux agonistes beta énantiomériquement purs, procédés pour leur préparation et leur utilisation comme médicament
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
WO2008037477A1 (fr) 2006-09-29 2008-04-03 Novartis Ag PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
EA016199B1 (ru) 2007-01-10 2012-03-30 Айрм Ллк Соединения и композиции как ингибиторы активирующей канал протеазы
US20100022770A1 (en) * 2007-01-25 2010-01-28 Boehringer Ingelheim International Gmbh Process for the manufacturing of beta mimetics
US8318935B2 (en) 2007-05-07 2012-11-27 Novartis Ag Organic compounds 75074
JP5455922B2 (ja) 2007-12-10 2014-03-26 ノバルティス アーゲー 有機化合物
ES2442930T3 (es) 2008-01-11 2014-02-14 Novartis Ag Pirimidinas como inhibidores de cinasas
WO2009150137A2 (fr) 2008-06-10 2009-12-17 Novartis Ag Composés organiques
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
SI2379507T1 (sl) 2008-12-30 2014-02-28 Pulmagen Therapeutics (Inflammation) Limited Spojine sulfonamida za zdravljenje respiratornih motenj
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
WO2010150014A1 (fr) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
WO2011050325A1 (fr) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions destinées au traitement de la mucoviscidose et d'autres maladies chroniques
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011098746A1 (fr) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
ES2886022T3 (es) * 2010-09-21 2021-12-16 Intekrin Therapeutics Inc Composiciones farmacéuticas sólidas antidiabéticas
WO2012107500A1 (fr) 2011-02-10 2012-08-16 Novartis Ag Composés de [1, 2, 4] triazolo [4, 3 -b] pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EP2755976B1 (fr) 2011-09-15 2018-07-18 Novartis AG 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituées en position 6 à activité tyrosine kinase
WO2013038386A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Composés hétérocycliques destinés au traitement de la mucosviscidose
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
WO2013038390A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Hétérocyclyle carboxamides n-substitués
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CA2868202C (fr) 2012-04-03 2021-08-10 Novartis Ag Produits combines comprenant des inhibiteurs de tyrosine kinase et leur utilisation
EP2906218B1 (fr) 2012-10-09 2016-12-14 Boehringer Ingelheim International GmbH Agoniste des récepteurs 2-adrénergiques utilisé dans le traitement de la toux
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CA2906542A1 (fr) 2013-03-15 2014-09-25 Intellikine, Llc Combinaison d'inhibiteurs de kinase et ses utilisations
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
AU2014391610B2 (en) 2014-04-24 2018-01-25 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
PT3134396T (pt) 2014-04-24 2019-12-16 Novartis Ag Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
CA2954862A1 (fr) 2014-07-31 2016-02-04 Novartis Ag Polytherapie
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
ES2900283T3 (es) 2016-12-20 2022-03-16 Inke Sa Proceso mejorado para la fabricación de clorhidrato de (R)-6-hidroxi-8-[1-hidroxi-2-[2-(4-metoxifenil)-1,1-dimetiletilaminoetil]-2H-1,4-benzoxazin-3(4H)-ona
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
AU2020290094B2 (en) 2019-06-10 2024-01-18 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
US20220306617A1 (en) 2019-08-28 2022-09-29 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
WO2021252577A1 (fr) * 2020-06-09 2021-12-16 Anovent Pharmaceutical (U.S.), Llc Formulation pharmaceutique contenant du bromure d'umeclidinium et du trifénatate de vilantérol
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
KR20020093083A (ko) * 2000-04-27 2002-12-12 베링거 잉겔하임 파르마 카게 신규한 완효성 베타모사체, 이의 제조방법 및 약제로서의이의 용도

Also Published As

Publication number Publication date
ES2326878T7 (es) 2014-03-11
MY136034A (en) 2008-07-31
CN1713914A (zh) 2005-12-28
ME00354B (fr) 2011-10-10
SI1562603T1 (sl) 2009-10-31
HUS1400011I1 (hu) 2022-02-28
ZA200502246B (en) 2006-01-25
IL167900A (en) 2013-06-27
UA81276C2 (en) 2007-12-25
EP1562603A2 (fr) 2005-08-17
TW200423943A (en) 2004-11-16
ATE430569T1 (de) 2009-05-15
CA2506082A1 (fr) 2004-06-03
RS20050361A (en) 2007-04-10
EA200500715A1 (ru) 2005-12-29
JP4317138B2 (ja) 2009-08-19
MXPA05005081A (es) 2005-07-01
BRPI0316264B1 (pt) 2019-04-09
NO334314B1 (no) 2014-02-03
EA008665B1 (ru) 2007-06-29
CN101817800A (zh) 2010-09-01
CN101735166A (zh) 2010-06-16
NL300650I2 (nl) 2017-11-02
NO20052883L (no) 2005-06-14
KR101092247B1 (ko) 2011-12-12
CO5570670A2 (es) 2005-10-31
RS51607B (sr) 2011-08-31
CY2014032I2 (el) 2015-12-09
NZ540661A (en) 2007-12-21
LU92433I2 (fr) 2014-06-24
JP2006508140A (ja) 2006-03-09
EP1562603B1 (fr) 2009-05-06
FR14C0049I2 (fr) 2015-07-24
KR20050075013A (ko) 2005-07-19
PL375270A1 (en) 2005-11-28
TWI343812B (en) 2011-06-21
CY2014032I1 (el) 2015-12-09
DK1562603T3 (da) 2009-09-07
ES2326878T3 (es) 2009-10-21
PL212238B1 (pl) 2012-08-31
CA2506082C (fr) 2011-06-21
LTC1562603I2 (lt) 2016-12-12
AU2003285326B2 (en) 2009-06-04
BR0316264A (pt) 2005-10-11
PE20040694A1 (es) 2004-11-23
DE10253282A1 (de) 2004-05-27
MEP53608A (en) 2011-05-10
EP2025338A1 (fr) 2009-02-18
AU2003285326A1 (en) 2004-06-15
HRP20050432A2 (en) 2006-06-30
HRP20050432B1 (en) 2012-01-31
PT1562603E (pt) 2009-06-18
NO2014005I1 (no) 2014-03-10
CY1110500T1 (el) 2015-04-29
BRPI0316264B8 (pt) 2021-05-25
ECSP055774A (es) 2005-11-22
WO2004045618A2 (fr) 2004-06-03
DE50311502D1 (de) 2009-06-18
WO2004045618A3 (fr) 2004-09-30
AR041969A1 (es) 2005-06-01
AR087241A2 (es) 2014-03-12
FR14C0049I1 (fr) 2014-08-08
EP1562603B3 (fr) 2014-01-08

Similar Documents

Publication Publication Date Title
BE2019C547I2 (fr)
BE2019C510I2 (fr)
BE2018C021I2 (fr)
BE2018C018I2 (fr)
BE2015C017I2 (fr)
BE2014C053I2 (fr)
BE2014C051I2 (fr)
BE2014C041I2 (fr)
FR14C0049I1 (fr)
BE2014C015I2 (fr)
BE2013C063I2 (fr)
BE2013C039I2 (fr)
BE2011C038I2 (fr)
JP2003122509A5 (fr)
JP2003116134A5 (fr)
BRPI0302144B1 (fr)
BRPI0215435A2 (fr)
BE2013C046I2 (fr)
JP2002273889A5 (fr)
JP2002339240A5 (fr)
JP2003222006A5 (fr)
JP2003210823A5 (fr)
JP2003220270A5 (fr)
BR0315835A2 (fr)
AU2002226740A1 (fr)